Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enoxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | EDNRA | P25101 | 1/20 | 0.77 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | HPGD | P15428 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.52 |
| ▸ | HTT | P42858 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enoxacin SCHEMBL29384458 | 0.88 | LMNA (1.00) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL2635855 | 0.88 | LMNA (1.00) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL33963 | 0.88 | LMNA (1.00) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL11283102 | 0.87 | LMNA (0.91) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL28451325 | 0.87 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL29896709 | 0.87 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL29108687 | 0.87 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL11289413 | 0.87 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL28065171 | 0.87 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL11023659 | 0.87 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729010-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130096069-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | CELLGATE, INC., A DELAWARE CORPORATION | 2013-04-18 | — | — | US | disclosed |
| US-8278264-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110123452-A1 | METAL OLIGOMERS AND POLYMERS AND THEIR USE IN BIOLOGY AND MEDICINE | NANOPROBES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2207598-A1 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE | Alcon Research, Ltd. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009064983-A1 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE | ALCON RESEARCH, LTD. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131303-A1 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE | ALCON RESEARCH, LTD. | 2009-05-21 | — | — | US | disclosed |
| US-20070213277-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC., A DELAWARE CORPORATION | 2007-09-13 | — | — | US | disclosed |
| EP-1372626-A4 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | CELLGATE INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7229961-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1372626-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | Cellgate Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030022831-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC., A DELAWARE CORPORATION | 2003-01-30 | — | — | US | disclosed |
| WO-2002067917-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | CELLGATE, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123452-A1 | METAL OLIGOMERS AND POLYMERS AND THEIR USE IN BIOLOGY AND MEDICINE | PICALM, CACYBP, CLTB | LMNA 924/4885CYP2C9 4796/4885ATP6V1B2 1224/4885 |
| US-20070213277-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | SLC7A1, ADM2, ARG1 | LMNA 766/4885CYP2C9 1948/4885ATP6V1B2 110/4885 |
| US-20130096069-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | SLC7A1, ADM2, ARG1 | LMNA 766/4885CYP2C9 1948/4885ATP6V1B2 110/4885 |
| US-20030022831-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | SLC7A1, ADM2, ARG1 | LMNA 766/4885CYP2C9 1948/4885ATP6V1B2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.